IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0722342
(1991-06-27)
|
발명자
/ 주소 |
- Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL)
|
출원인 / 주소 |
- Noven Pharmaceuticals, Inc. (Miami FL 02)
|
인용정보 |
피인용 횟수 :
174 인용 특허 :
0 |
초록
▼
The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permea
The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permeation rate of the drug into and through the dermis. In one embodiment, a dermal composition of the present invention comprises a drug, an acrylate polymer, and a polysiloxane. The dermal compositions can be produced by a variety of methods known in the preparation of drug-containing adhesive preparations, including the mixing of the polymers, drug, and additional ingredients in solution, followed by removal of the processing solvents. The method and composition of this invention permit selectable loading of the drug into the dermal formulation and adjustment of the delivery rate of the drug from the composition through the dermis, while maintaining acceptable shear, tack, and peel adhesive properties.
대표청구항
▼
A pressure sensitive adhesive transdermal drug delivery system comprising: (a) a blend consisting essentially of about 2% to about 96% by weight of a polyacrylate and about 98% to about 4% by weight of a polysiloxane, said blend being in an amount of about 99% to about 50% by weight of said system a
A pressure sensitive adhesive transdermal drug delivery system comprising: (a) a blend consisting essentially of about 2% to about 96% by weight of a polyacrylate and about 98% to about 4% by weight of a polysiloxane, said blend being in an amount of about 99% to about 50% by weight of said system and wherein said ratio of polyacrylate to polysiloxane is from about 2:98 to about 86:14 by weight of said blend and wherein the permeation rate is controlled by varying the relative proportions of the polymers; (b) a drug in the amount of about 0.3% to about 50% by weight of said system and wherein the drug is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrates, quinidine sulfate, procainamide, bendroflumethiazide, chlorothiazide, nifedipine, nicardipine, timolol, propranolol, verapamil, diltiazem, captopril, clonidine, prazosin, testosterone, estropipate, 17b17b17b19-norprogesterone, norethindrone, norethindrone acetate, melengestrol, chloramdinone, ethisterone, medroxyprogesterone acetate, hydroxyprogesterone caproate, ethynodiol diacetate, norethynodrel, 17-alpha-hydroxyprogesterone, dydrogesterone, dimethisterone, ethinylestrenol, norgestrel, demegestone, promegestone, megestrol acetate, buprenorphine, naloxone, haloperidol, codeine, lidocaine, tetracaine, dyclonine, dibucaine, cocaine, procaine, mepivacaine, bupivacaine, etidocaine, prilocaine, benzocaine, fentanyl, hydrocortisone, cortisone, prednisolone, prednisone, halcinonide, betamethasone, ibuprophen, naproxen, fenoprofen, fenbufen, indoprofen, ketoprofen, suprofen, indomethacin, piroxicam, aspirin, salicylic acid, chlorpheniramine, theophilline, albuterol, terbutaline, metaproterenol, carbuterol, fenoterol, quinterenol, rimiterol, solmefamol, soterenol, tretoquinol, dopamine, phenylpropanolamine, epinephrine, pilocarpine, choline, acetylcholine, methacholine, carbachol, bethanechol, muscarine, arecoline, scopolamine, eucatropine, atropine, penicillin, tetracycline, papaverine, tamoxifen, dextroamphetamine, mazindol, alprazolam, chlordiazepoxide, clorazeptate, halazepam, oxazepam, prazepam, chlonazepam, flurazepam, triazolam, lorazepam, diazepam, thiopropazate, chlorpromazine, triflupromazine, mesoridazine, piperacetazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chlorprothixene, thiothixene, bromperidol, loxapine, molindone, pyrimethamine, misoprostol, enprostil, levodopa, selegiline, baclofene, and mixtures thereof; (c) optionally, an effective amount of a co-solvent for the drug, said amount being up to about 30% by weight of said system; and (d) optionally, an effective amount of an enhancer, said amount being up to about 20% by weight of said system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.